Top Page
Biome Australia Ltd
(Sydney:BIO)
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Biome Australia Ltd Business Overview & Revenue Model
Biome Australia Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.42M | 18.42M | 13.01M | 7.24M | 4.11M | 2.32M |
| Gross Profit | 11.26M | 11.26M | 7.91M | 4.06M | 2.38M | 1.07M |
| EBITDA | 143.57K | 143.57K | -1.58M | -3.15M | -4.65M | -5.39M |
| Net Income | 214.66K | 214.66K | -1.67M | -3.08M | -4.54M | -5.38M |
Balance Sheet | ||||||
| Total Assets | 11.97M | 11.97M | 8.28M | 7.56M | 8.25M | 11.09M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 2.75M | 2.87M | 2.26M | 5.49M | 634.61K |
| Total Debt | 3.07M | 3.07M | 1.30M | 1.15M | 467.05K | 81.00K |
| Total Liabilities | 7.29M | 7.29M | 5.37M | 3.97M | 1.73M | 920.00K |
| Stockholders Equity | 4.68M | 4.68M | 2.90M | 3.59M | 6.53M | 10.17M |
Cash Flow | ||||||
| Free Cash Flow | -2.86M | -2.86M | -185.41K | -3.90M | -3.55M | -2.46M |
| Operating Cash Flow | -2.82M | -2.82M | -163.81K | -3.50M | -3.42M | -2.39M |
| Investing Cash Flow | -200.38K | -200.38K | -21.61K | -400.94K | -99.34K | -28.77K |
| Financing Cash Flow | 2.90M | 2.90M | 793.17K | 665.21K | 8.40M | 2.58M |
Biome Australia Ltd Technical Analysis
Biome Australia Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | ― | 465.00 | 5.66% | ― | 41.57% | ― | |
46 Neutral | AU$14.28M | ― | -143.71% | ― | 306.88% | ― | |
42 Neutral | AU$8.54M | ― | ― | ― | ― | ― | |
40 Underperform | AU$2.17M | ― | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$4.61M | ― | -628.72% | ― | ― | 31.87% | |
27 Underperform | AU$3.96M | ― | -205.70% | ― | ― | 1.03% |
Biome Australia Ltd Corporate Events
Biome Australia Limited reported record sales revenue for the quarter ending June 2025, with a significant increase in both quarterly and annual sales figures. The company achieved a quarterly EBITDA of $78k and anticipates exceeding $900k for the fiscal year 2025. Despite a net operating cash outflow, Biome increased its cash balance and maintained a gross margin of 61%. Strategic investments were made to support future growth, including the launch of a new product range and international market expansion.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced an upcoming investor webinar scheduled for July 31, 2025, where Managing Director Blair Vega Norfolk will provide a company update. This event offers an opportunity for investors to engage with the company, submit questions, and gain insights into Biome’s operations and strategic direction. The webinar reflects Biome’s commitment to maintaining transparency with stakeholders and highlights its proactive approach to investor relations.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has reported a significant increase in international sales revenue for FY25, achieving $1.5 million, a 69% rise from the previous fiscal year. The company has secured strategic distribution partnerships in Ireland, New Zealand, and Canada, positioning itself for substantial growth in FY26 by leveraging these new channels to enhance its market reach and brand recognition in the global health and wellness sector.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced record sales revenue for the fiscal year 2025, achieving approximately $18.4 million, marking a 41% growth compared to the previous year. The company also reported its strongest quarter to date, with Q4 sales exceeding $5 million, and record monthly sales in June of $2.1 million, indicating significant growth and positive market positioning.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced record sales revenue for the fiscal year 2025, achieving approximately $18.4 million, a 41% increase from the previous year. The company also reported its strongest quarter to date, with Q4 sales reaching over $5 million and June sales hitting $2.1 million, marking a 50% increase compared to the previous corresponding period. These results position Biome to meet its Vision 27 forecast of $75 million in cumulative sales for FY25-27, indicating a strong trajectory for future growth.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced the application for quotation of 1,042,484 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move, involving securities issued under an employee incentive scheme, is part of the company’s strategy to enhance its market presence and operational flexibility, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced a proposed issue of 244,442 ordinary fully paid securities, with the issuance date set for June 27, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market presence and providing additional capital for its operations.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced an investor webinar scheduled for June 5th, where the company’s Managing Director, Blair Vega Norfolk, will introduce the new Chair, Geoff Sam OAM, and provide a general business update. This event reflects Biome’s ongoing commitment to engaging with investors and stakeholders, potentially impacting its market positioning by showcasing leadership changes and business strategies.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Ltd has announced the cessation of Ilario Faenza as a director, effective May 20, 2025. Faenza held significant interests in the company, including 1,534,796 fully paid ordinary shares as a registered holder and 1,421,809 shares through FDV Investments Pty Ltd, an entity he controls. This change in directorship may impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
Biome Australia Limited has announced the appointment of Geoff Sam as the new Chairman of the Board of Directors, following the resignation of Ilario Faenza. Geoff Sam, who brings significant expertise in healthcare and pharmaceutical manufacturing, is expected to play a crucial role in guiding Biome through its Vision 27 strategic plan and optimizing manufacturing processes. His leadership is anticipated to support the ongoing commercial development of Biome’s products both locally and internationally, aligning with the company’s growth objectives.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.